

REMARKS

In view of the above amendments and the following remarks, reconsideration of the outstanding office action is respectfully traversed.

The rejection of claims 1-12, 14-28, 30-36, 42-47, and 49 under 35 U.S.C. § 102(b) for anticipation by Tirelli et al., "Differential Effects of Direct and Indirect Dopamine Agonists on the Induction of Gnawing in C57B1/6J Mice," *The Journal of Pharmacology and Experimental Therapeutics* 273(1):7-15 (1995) ("Tirelli") is respectfully traversed in view of the above amendments.

~~The rejection of claims 1-12, 14-28, 30-36, 42-27, and 49 under 35 U.S.C. § 102(b) for anticipation by Salama et al., "Antigenic Determinants Responsible for the Reactions of Drug-Dependent Antibodies with Blood Cells," *British Journal of Haematology* 78:535-539 (1991) ("Salama") is respectfully traversed in view of the above amendments.~~

The rejection of claims 1-12, 14-28, 30-36, 42-47, and 49 under 35 U.S.C. § 102(b) as anticipated by Switzerland Patent No. CH 538477 to Rheiner ("Swiss Application") is respectfully traversed in view of the above amendments.

The rejection of claims 1-12, 14-28, 30-36, 42-47, and 49 under 35 U.S.C. § 102(b) as anticipated by German Patent No. DE 2062001 to Rheiner ("German Application") is respectfully traversed in view of the above amendments.

The rejection of claims 1-12, 14-28, 30-36, 42-47, and 49 under 35 U.S.C. § 103 for obviousness over the Swiss Application is respectfully traversed in view of the above amendments.

The rejection of claims 1-12, 14-28, 30-36, 42-47, and 49 under 35 U.S.C. § 103 for obviousness over the German Application is respectfully traversed in view of the above amendments.

The rejection of claims 30, 33, and 34 under 35 U.S.C. § 103 for obviousness over Tirelli is respectfully traversed in view of the above amendments.

With regard to the August 27, 2001, Information Disclosure Statement, attached are the accompanying PTO-1449 forms which have been revised to include the complete citation information for the Jorgenson, "Preparation of Ketones from Reaction of Organolithium Reagents with Carboxylic Acids," *Organic Reactions*, pp. 1-97 (1977) and Blomberg et al., "The Barbier Reaction – A One Step Alternative for Synthesis via

Organomagnesium Compounds," *Synthesis*, pp. 18-30 (1970) references. Copies of these references are also enclosed.

The rejection of claims 1-12, 14-28, 30-36, 42-47, and 49-92 under 35 U.S.C. § 112 (first paragraph) for failure to satisfy the written description requirement is respectfully traversed in view of the above amendments.

The rejection of claims 1-12, 14-28, 30-36, 42-47, and 49-92 under 35 U.S.C. § 112 (second paragraph) is respectfully traversed in view of the above amendments.

The rejection of claims 1-5, 10, 16, 28, 35, 36, 42, 45, 51-55, 84-86, and 89 under 35 U.S.C. § 102 as anticipated by U.S. Patent No. 4,340,600 to Brenner et al.

("Brenner") is respectfully traversed in view of the above amendments.

Brenner discloses 4-phenyl-1,2,3,4-tetrahydroisoquinolines and their use in renal dilating methods. However, as to the pending claims, Brenner fails to teach the limitation "wherein if R^4 is hydrogen, then R^3 cannot be hydrogen or halogen and n cannot be 0, and R^9 cannot be hydrogen". Since Brenner fails to teach or suggest compounds satisfying this limitation, it cannot anticipate the claimed invention. Accordingly, the rejection under 35 U.S.C. § 102 based on Brenner should be withdrawn.

In view of all the foregoing, it is submitted that this case is in condition for allowance and such allowance is earnestly solicited.

Date: December 23, 2003

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (585) 263-1304
Facsimile: (585) 263-1600

Respectfully submitted,



Michael L. Goldman
Registration No. 30,727

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]

I hereby certify that this correspondence is being:

- ☒ deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop _____, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450
- ☐ transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at

(703)
12/23/03
Date


Signature

Wendy L. Barry
Type or Print Name